Categories
Change Password!
Reset Password!
To evaluate the impact of Febuxostat versus placebo on joint damage among hyperuricemic patients with early gout.
The urate-lowering therapy is most recommended therapy for the
treatment of gout. However, these drugs were not provided up to mark relief
from the gout symptoms. Therefore, a randomized study conducted by Dalbeth N et
al used Febuxostat 40 mg and reported the significant improvement in
magnetic resonance imaging (MRI) synovitis and reduced gout flares in gout
patients.
To evaluate the impact of Febuxostat versus placebo on
joint damage among hyperuricemic patients with early gout.
A total of 314 participants with early gout and
hyperuricemia were either received 40 mg Febuxostat, increased up to 80 mg if
UA level was ≥6.0 mg/dl on day 14 or placebo. The primary outcome studied was
the mean change in the modified Sharp/van der Heijde erosion score for the
single affected joint from baseline to month 24. The change from baseline to
month 24 in the erosion, the incidence of gout flares, Rheumatoid Arthritis
Magnetic Resonance Imaging Scoring (RAMRIS) for synovitis, serum UA levels, and
edema in the single affected joint were some of the additional efficacy
outcomes that also evaluated during the analysis. Safety was evaluated all through
the investigation.
No significant change was seen in the joint erosion over
two years with the Febuxostat treatment. A minimal mean change was observed in
the modified Sharp/van der Heijde erosion score from baseline to month 24 for
the single affected joint, with no between-group variations. Although serum UA
control improved, the overall incidence of gout flares reduced and RAMRIS
synovitis score at month 24 improved with Febuxostat treatment as compared to
the placebo. No significant safety concerns were recorded.
Urate-lowering treatment with Febuxostat decreased the
incidence of gout flares and enhanced magnetic resonance imaging-determined
synovitis among individuals with early gout.
Arthritis Rheumatol. 2017 Dec;69(12):2386-2395
Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study
Dalbeth N et al.
Comments (0)